Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | AHR | P35869 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 11/20 | 0.46 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.40 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.40 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.40 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21742008 | 0.88 | SMN1; SMN2 (0.61) | SMN1; SMN2L3MBTL1AHRHSD11B1CHRM2 | |
| SCHEMBL4388586 | 0.87 | SMN1; SMN2 (0.67) | SMN1; SMN2L3MBTL1AHRCHRM2 | |
| SCHEMBL11681741 | 0.80 | L3MBTL1 (0.57) | SMN1; SMN2L3MBTL1AHRCHRM2 | |
| SCHEMBL6071170 | 0.79 | SMN1; SMN2 (0.61) | SMN1; SMN2L3MBTL1AHRNR1H3 | |
| SCHEMBL21742080 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL1AHRABCC9ABCC8 | |
| SCHEMBL30020222 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL1AHRABCC9ABCC8 | |
| SCHEMBL3718198 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL1AHRABCC9ABCC8 | |
| SCHEMBL13237137 | 0.79 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL1AHRCHRM2 | |
| SCHEMBL6921056 | 0.79 | SMN1; SMN2 (0.67) | SMN1; SMN2L3MBTL1AHRCHRM2 | |
| SCHEMBL946635 | 0.79 | SMN1; SMN2 (0.67) | SMN1; SMN2L3MBTL1AHRCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3572413-B1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE1 INHIBITOR | SHIJIAZHUANG SAGACITY NEW DRUG DEV CO LTD (CN) | 2021-11-03 | — | — | EP | disclosed |
| EP-3611164-A1 | PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT | Mitsui Chemicals Agro, Inc. (JP) | 2020-02-19 | — | — | EP | disclosed |
| US-8119819-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20100016259-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016259-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | MLYCD, ME3, ACACA | SMN1; SMN2 2783/4885L3MBTL1 1362/4885AHR 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.